Skip to main navigation Skip to search Skip to main content

Diabetes mellitus and male aging: Pharmacotherapeutics and clinical implications

  • Swathi Putta
  • , Ilaria Peluso
  • , Nagendra Sastry Yarla
  • , Eswar Kumar Kilari
  • , Anupam Bishayee
  • , Da Yong Lu
  • , George E. Barreto
  • , Ghulam Md Ashraf
  • , Luciana Scotti
  • , Marcus T. Scotti
  • , Rajeev K. Singla
  • , Thonos Alexiou
  • , Atanas G. Atanasov
  • , Vadim V. Tarasov
  • , P. Veera Bramhachari
  • , Sarat Babu Imandi
  • , Madhuri Chintala
  • , Bechan Sharma
  • , Marcella Reale
  • , Rosanna Filosa
  • Gjumrakch Aliev, Mohammad Amjad Kamal*
*Corresponding author for this work
  • Andhra University
  • Council for Agricultural Research and Economics
  • Gandhi Institute of Technology and Management
  • Florida International University
  • Shanghai University
  • Universidad Javeriana
  • Universidad Autónoma de Chile
  • King Fahd Medical Research Center (GMA)
  • King Abdulaziz University
  • Universidade Federal da Paraíba
  • Netaji Subhas University of Technology
  • Novel Global Community Educational Foundation
  • Institute of Genetics and Animal Breeding of the Polish Academy of Sciences
  • Sechenov First Moscow State Medical University
  • Krishna University
  • Andhra Medical College
  • University of Allahabad
  • Gabriele d'Annunzio University
  • University of Campania Luigi Vanvitelli
  • Russian Academy of Sciences
  • GALLY International Biomedical Research Consulting LLC
  • University of Atlanta
  • Enzymoics

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)

Abstract

Andropause or male menopause is defined as androgen decline and onset of hypogonadism in the aging male. Testosterone deficiency in adult male is associated with diabetes mellitus, coronary artery disease, and heart failure. Type 2 diabetic male patients aged above 30 years showed low testosterone levels which is common in diabetic men and had symptoms of hypogonadism. Male sexual dysfunction among diabetic patients can include disorders of libido, ejaculatory problems, and erectile dysfunctions are common among people with diabetes, particularly in older men who had diabetes for years. Older diabetics tend to have both impaired insulin release as well as insulin resistance. There is growing evidence indicating the pathophysiological connections among the mechanisms of oxidative damage by disruption of the oxidative balance, increased levels of enzymatic glycation products in testicular region and glucose transporters, obesity and proinflammatory cytokines in male infertile patients with diabetes. Epidemiological studies suggest that many clinical findings in diabetics are linked to low testosterone levels. This article reviews pathophysiological mechanisms, observational studies, and clinical implications of testosterone therapy in type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)4475-4483
Number of pages9
JournalCurrent Pharmaceutical Design
Volume23
Issue number30
DOIs
Publication statusPublished - 1 Aug 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Andropause
  • Diabetes mellitus
  • Hypogonadism
  • Insulin
  • Proinflammatory cytokines
  • Testosterone

Fingerprint

Dive into the research topics of 'Diabetes mellitus and male aging: Pharmacotherapeutics and clinical implications'. Together they form a unique fingerprint.

Cite this